# EDGAR Filing Document

**Accession Number:** 0001873875
**File Stem:** 0001213900-25-121876
**Filing Date:** 2025-12
**Character Count:** 5288
**Document Hash:** 5a3711c84ec3a4d7f70b4086aaac24b2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-121876.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001213900-25-121876

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Incannex Healthcare Inc.
- **CENTRAL INDEX KEY:** 0001873875
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41106
- **FILM NUMBER:** 251573300

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8 CENTURY CIRCUIT
- **STREET 2:** STE. 105
- **CITY:** NORWEST NSW
- **NON US STATE TERRITORY:** NSW
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 409 840 786

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8 CENTURY CIRCUIT
- **STREET 2:** STE. 105
- **CITY:** NORWEST NSW
- **NON US STATE TERRITORY:** NSW
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Incannex Healthcare Ltd
- **DATE OF NAME CHANGE:** 20210720

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant ☒ <br> Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Under §240.14a-12

**Incannex Healthcare Inc.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required <br> ☐ Fee paid previously with preliminary materials <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

**SUPPLEMENT TO THE PROXY STATEMENT FOR THE**

**ANNUAL MEETING OF STOCKHOLDERS OF**

**INCANNEX HEALTHCARE INC.**

**TO BE HELD ON DECEMBER 18, 2025**

This supplement, dated December 16, 2025, amends and supplements the Proxy Statement of Incannex Healthcare Inc. ("we" or the "Company"), dated October 27, 2025 (the "Proxy Statement"), relating to the 2025 annual meeting of stockholders of the Company (the "Annual Meeting"), with the following information.

**Expected Adjournment of Annual Meeting**

The Company has been advised that Proposal No. 2, relating to the ratification of the appointment of its independent registered accounting firm (the "Auditor Ratification Proposal"), has been **classified as a non-routine proposal due solely to an administrative error by the Company's transfer agent**. As a result of this classification, if a stockholder's shares are held in "street name" and voting instructions are not provided to the applicable bank, broker, or other nominee, such intermediary currently lacks authority to vote those shares on the Auditor Ratification Proposal.

Upon becoming aware of this transfer agent error, the Company promptly engaged with the transfer agent and other relevant parties to seek reclassification of the proposal so that the Auditor Ratification Proposal would be treated as routine, which would permit brokers, banks, and other nominees to exercise discretionary voting authority for shares held in street name. However, there can be no assurance that the Auditor Ratification Proposal will be reclassified as routine, and even if such reclassification is ultimately achieved, the Company does not expect that it will occur on or prior to the Annual Meeting scheduled for December 18, 2025.

Accordingly, as a direct result of this transfer agent error, the Company expects that the Annual Meeting will likely be adjourned in order to allow additional time to reclassify the proposal and to solicit the requisite votes to obtain a quorum. If your shares are held in "street name," you are strongly encouraged to promptly provide voting instructions to your bank, broker, or other nominee.

 ****

***The Company strongly encourages all stockholders to promptly vote.***

**Important Information**

The Company has filed a definitive Proxy Statement with the Securities and Exchange Commission and has furnished to its stockholders a Proxy Statement in connection with the solicitation of proxies for the Annual Meeting. The Company advises its stockholders to read the Proxy Statement relating to the Annual Meeting, as amended and supplemented, including as amended and supplemented by this supplement, because it contains important information.

Except as described in this supplement, none of the items or information presented in the Proxy Statement is affected by this supplement. This supplement does not provide all of the information that is important to your voting decisions at the Annual Meeting. The Proxy Statement contains other important additional information. We encourage you to carefully read this supplement together with the Proxy Statement.